Last $2.13 USD
Change Today +0.01 / 0.47%
Volume 515.5K
PRAN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
OTC US
Stuttgart
As of 5:20 PM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

prana biotechnology ltd-adr (PRAN) Snapshot

Open
$2.11
Previous Close
$2.12
Day High
$2.15
Day Low
$2.04
52 Week High
01/30/14 - $13.29
52 Week Low
05/7/14 - $1.47
Market Cap
104.1M
Average Volume 10 Days
1.1M
EPS TTM
--
Shares Outstanding
48.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PRANA BIOTECHNOLOGY LTD-ADR (PRAN)

Related News

No related news articles were found.

prana biotechnology ltd-adr (PRAN) Related Businessweek News

View More BusinessWeek News

prana biotechnology ltd-adr (PRAN) Details

Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of neurological disorders in Australia. It primarily focuses on the Alzheimer‘s, Parkinson‘s, and Huntington‘s diseases, as well as various cancer and age-related macular degeneration. The company’s product line includes PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer’s disease, as well as in Phase IIa clinical trials to treat Huntington’s disease. Its preclinical products comprise PBT434 for the treatment of Alzheimer’s disease; and PBT519 to treat brain cancer. The company was formerly known as Prana Corporation Ltd. and changed its name to Prana Biotechnology Limited in January 2000. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.

Founded in 1997

prana biotechnology ltd-adr (PRAN) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: A$426.5K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$77.3K
Chief Operating Officer
Total Annual Compensation: A$318.0K
Compensation as of Fiscal Year 2013.

prana biotechnology ltd-adr (PRAN) Key Developments

Prana Biotechnology Limited Receives US Food and Drug Administration Orphan Drug Designation for PBT2 for Huntington Disease

Prana Biotechnology Limited has announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation to PBT2 for the treatment of Huntington Disease. Orphan drug designation is granted by the FDA to promote the development of drugs for diseases affecting less than 200,000 people in the United States. Orphan drug designation entitles Prana to seven years of market exclusivity for the use of PBT2 in the treatment of Huntington disease; protocol assistance by the FDA to optimize drug development in the preparation of a dossier that will meet regulatory requirements; and reduced fees associated with applying for market approval. The company will also be applying for Orphan Drug designation in Europe and other jurisdictions. Prana announced in February 2014 that its lead MPAC (Metal Protein Attenuating Compound) PBT2 had met its primary end point of safety and tolerability, and improved measures of cognitive performance - a secondary endpoint in its Reach2HD Phase 2 clinical trial involving 109 people with Huntington disease. Prana is preparing its Post Phase 2 Trial dossier for submission to the FDA to commence discussions on the next development steps for PBT2.

Prana Biotechnology Limited Reports Consolidated Earnings Results for the Year Ended June 30, 2014

Prana Biotechnology Limited reported consolidated earnings results for the year ended June 30, 2014. For the period, the company reported revenue from ordinary activities of AUD 363,775 compared to AUD 150,867 a year ago, which is interest received on the group's bank accounts. The company has incurred a loss of AUD 13,329,239 compared to AUD 7,787,242 a year ago. This loss has increased due to an increase in R&D expenditure for the period offset by an increase in other income recognized under an Australian government tax incentive scheme introduced July 1, 2011. Loss before income tax expense was AUD 13,329,239 compared to AUD 7,787,242 a year ago. Diluted loss per share was 3.11 cents compared to 2.30 cents a year ago. Net operating cash out flows were AUD 13,788,974 compared to AUD 7,951,254 a year ago. Payment for purchases of plant and equipment was AUD 23,047 compared to AUD 22,000 a year ago. Net Tangible Assets per Share was 7.71 cents compared to 3.66 cents a year ago.

Prana Biotechnology Limited Reports Consolidated Earnings Results for the Quarter Ended June 30, 2014

Prana Biotechnology Limited reported consolidated earnings results for the quarter ended June 30, 2014. Revenue was $93,135,000 compared to $131,863,000 a year ago. Loss from operating activities were $2,124,000 compared to income from operating activities was $2,270,000 a year ago. Loss before tax was $2,957,000 compared to profit before tax of $1,507,000 a year ago. Loss attributable to owners of the company was $4,432,000 compared to profit attributable to owners of the company of $607,000 a year ago. Net cash generated from operating activities was $5,932,000 compared to $14,923,000 a year ago. Purchase of property, plant and equipment amounted to $703,000 compared to $1,078,000 a year ago. Basic and diluted loss per share was 0.37 cents compared to basic and diluted EPS of 0.05 cents a year ago. The contraction in revenue was due to a slowdown in private construction activities, following the introduction of cooling measures to the private residential property sector. The effect of such measures was adversely felt by the construction sector in Singapore which has led to dampened construction demand.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRAN:US $2.13 USD +0.01

PRAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRAN.
View Industry Companies
 

Industry Analysis

PRAN

Industry Average

Valuation PRAN Industry Range
No financial data is available for PRAN.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRANA BIOTECHNOLOGY LTD-ADR, please visit www.pranabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.